Last reviewed · How we verify
Up4U (DIQUAFOSOL)
At a glance
| Generic name | DIQUAFOSOL |
|---|---|
| Sponsor | Santen Pharmaceutical |
| Target | P2Y purinoceptor 2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 2010 |
Approved indications
- Tear film insufficiency
Common side effects
Key clinical trials
- Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease (PHASE4)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK (NA)
- Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (NA)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Up4U CI brief — competitive landscape report
- Up4U updates RSS · CI watch RSS
- Santen Pharmaceutical portfolio CI